Unveiling ctDNA Response: Immune Checkpoint Blockade Therapy in a Patient with POLE Mutation-Associated Early-Onset Colon Cancer.

Ramya Ramachandran, Marisa Cannon, Supriya Peshin, Madappa Kundranda, Aaron J Scott

Abstract readCase Reports

In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Comprehensive Review of Immunotherapy in Colorectal Cancer: From Mechanisms to Nursing Interventions.ImmunoTargets and therapy · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ramya RamachandranDepartment of Internal Medicine, University of Arizona, Tucson, AZ 85724, USA.

Marisa CannonCollege of Medicine, University of Arizona, Tucson, AZ 85724, USA.

Supriya PeshinDepartment of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.ORCID 0000-0002-3895-9474

Madappa KundrandaDivision of Cancer Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA.

Aaron J ScottDivision of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ 85724, USA.ORCID 0000-0002-0301-3072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common malignancy worldwide and the second leading cause of cancer-related mortality in the United States. The incidence of early-onset colorectal cancer (EOCRC) has been increasing over the past several decades. While the etiologies for this rising incidence remain unclear, genetic factors likely play an important role. DNA polymerase epsilon (POLE) mutations occur at a higher rate than average-onset colorectal cancer (AOCRC). DNA polymerase epsilon (Pol ε) is a high-fidelity, processive polymerase that is a promising target for immune checkpoint inhibitors due to its association with various human malignancies, including colorectal cancer. EOCRC remains a major area of focus, and POLE mutations leading to the high-TMB subtype constitute a potential therapeutic target.

Indexed as

Circulating Tumor DNAColonic NeoplasmsDNA Polymerase IIImmune Checkpoint InhibitorsPoly-ADP-Ribose Binding ProteinsFemaleHumansMaleMutationCirculating Tumor DNADNA Polymerase IIImmune Checkpoint InhibitorsPOLE protein, humanPoly-ADP-Ribose Binding Proteinscase reportctDNAearly onset colorectal cancerIpilimumabNivolumabPOLE

Identifiers

PMID40710181

DOI10.3390/curroncol32070370

PMCPMC12293316

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.